Injectable bisphosphonates in the treatment of postmenopausal osteoporosis
- 1 August 2003
- journal article
- review article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 15 (4) , 271-283
Abstract
Osteoporosis is a “silent” disease and the patient has usually no clue of it until the occurrence of a fragility fracture. Prevention requires a continuous daily treatment that could be uncomfortable to the patient. Besides the recently introduced weekly oral schedules, injectable bisphosphonates have often been used as an off-label option to ameliorate compliance. In general, although with different efficiency, almost all injectable bisphosphonates can improve bone mineral density and suppress bone resorption markers. The effect of intravenous infusions of bisphosphonates are, to a large extent, similar to equivalent intramuscular administrations, but doses and dosing intervals represent the critical issues. Pain at the injection site and acute phase reactions are relatively common to intramuscular clodronate and intravenous infusions of nitrogen-containing bisphosphonates, respectively. Under certain circumstances, intermittent treatment with injectable bisphosphonates might represent a feasible alternative when compliance is at risk.Keywords
This publication has 61 references indexed in Scilit:
- Zoledronate treatment in active Paget's diseaseAnnals of the Rheumatic Diseases, 2003
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2001
- Chronic Intravenous Aminobisphosphonate Therapy Increases High-Density Lipoprotein Cholesterol and Decreases Low-Density Lipoprotein CholesterolJournal of Bone and Mineral Research, 2000
- IbandronateDrugs, 1999
- The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding studyBone, 1996
- Continuous and cyclical clodronate therapies and bone density in postmenopausal bone lossObstetrics & Gynecology, 1996
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapyJournal of Bone and Mineral Research, 1995